Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
J. Clin. Invest. Christopher T. Ritchlin, et al. 111:821 doi:10.1172/JCI16069 [
Go to this article.]
Figure 9Anti–TNF-α therapy reduces OCP frequency in patients with PsA. (
a) PBMCs from five PsA patients were cultured to determine the OCP frequency before and after 12 weeks of anti–TNF-α therapy (four patients with etanercept and one with infliximab). The data are expressed as osteoclasts per 10
6 PBMCs. The number of OCPs in peripheral blood was significantly reduced in all of the patients (
P < 0.001). (
b) The percentage of CD11b
+ PBMCs significantly declined in four patients with erosive PsA, following 2 weeks of etanercept therapy, as determined by FACS (
P < 0.026). (
c and
d) Representative histograms of CD14/CD11b staining from a PsA patient before (
c) and after (
d) etanercept therapy.
